Acepodia is emerging as one of the world’s few developers of antibody-drug conjugates (ADCs) preparing to advance into the clinic with a dual payload-fixed design of targeted cancer therapy.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?